Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in Recurrent High-Grade Glioma
NCT04424966Phase 1Terminated
- Sponsor
- Ivy Brain Tumor Center
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of infigratinib in glioma, sponsored by Ivy Brain Tumor Center. Primary endpoints: Total Concentration of Infigratinib in Enhancing and Non-Enhancing Tumor Tissue, Unbound Concentration of Infigratinib in Enhancing and Non-Enhancing Tumor Tissue and 5 more. Started Jul 2020; status: terminated.
02
Drugs
infigratinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04424966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04424966.